Coronary Artery Disease and Myocardial Infarction

TCT 22: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD

Yuhei Kobayashi,

Watch time: 07:21
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2:56
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3:24
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3:00
4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab

Lorenz Räber,

ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)

Steven E Nissen,

ACC 22: Results from the TRANSLATE-TIMI 70 Trial

ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease

Frederik Zimmermann,

ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall,

RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes

Nick Curzen,

Heather Currie , Christine Williams ,

Edward T Carreras , Donna M Polk ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2:56
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3:00

Charles H Hennekens , Danielle Hollar , Arthur S Agatston ,

Sergio Fazio ,

Abdulah Alrifai , Mohamad Kabach , Jonathan Nieves , et al

Marc Sirol ,

Donald E Cutlip ,

Antonio Gutierrez , Sunil V Rao ,

Marsha M Neumyer , Bill Bertolino ,

Sara C Martinez , Sharonne N Hayes ,

Media

TCT 22: FAME 3: FFR-Guided PCI Vs CABG in Pts With Multivessel CAD

Yuhei Kobayashi,

Watch time: 07:21
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2:56
FOURIER-OLE: The Trial in Context

Marc S Sabatine,

Watch time: 3:24
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3:00

Yassir Javaid, , , et al

4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos

Erin D Michos,

Secondary Analysis of CANTOS Finds LDL & HDL Predict Residual Risk of Atherosclerotic Events

Paul M Ridker,

ACC 22: PACMAN-AMI Shows Reduced Plaque Regression in AMI Patients Treated with Alirocumab

Lorenz Räber,

ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)

Steven E Nissen,

ACC 22: Results from the TRANSLATE-TIMI 70 Trial

ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease

Frederik Zimmermann,

ACC 2022 Late-breaker Discussion: The SuperWIN Trial

Dylan L Steen, Harriette Van Spall,

RIPCORD 2: FFR During Angiography Did Not Improve Patient Outcomes

Nick Curzen,

ACC 2021: Findings From the RESCUE Trial

Paul M Ridker,

ACC 2021 Discussion: The STRENGTH Study

Steven E Nissen, Harriette Van Spall,

What to Expect at TCTAP 2021

Bill D Gogas, Duk-Woo Park,

AHA 2020: The STRENGTH Trial

AHA 2020: Evinacumab safety and efficacy in HoFH

TCT Connect 2020 Discussion: The VOYAGER PAD Study

Mirvat Alasnag, ,

ESC 2020: APOC-III Reduction in Cardiovascular Disease

Jean-Claude Tardif,

View From The Thoraxcenter: What's Hot at ESC 2020

Nicolas M Van Mieghem, Joost Daemen,

ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c

ACC 2020: Primary Results of the Voyager PAD Trial

Marc P Bonaca,

AHA 2019: Empagliflozin on Erythropoietin Levels

David Mazer,

AHA 2019: Updates from the EVAPORATE Study

Matthew J Budoff,

AHA 2019: Updates from ISCHEMIA-CKD

Sripal Bangalore,

AHA 2018: REDUCE-IT - Dr Pradeep Natarajan

Pradeep Natarajan,

View from the Thoraxcenter - Wrap up of AHA 2018

Nicolas M Van Mieghem, Joost Daemen,

ESC 2018: CAMELLIA-TIMI 61

Erin A Bohula,

Ajay J Kirtane,

Articles

Coronary CT Angiography-derived FFR

Lavanya Cherukuri

,

Divya Birudaraju

,

Matthew J Budoff

,

Published:

23 April 2021

Citation:

US Cardiology Review 2021;15:e06.

DOI:

https://doi.org/10.15420/usc.2020.24
  • Views: Views 1279
  • Downloads: Downloads 65

Current Evidence and Future Directions of PCSK9 Inhibition

Jiaqian Xu

,

Michael D Shapiro

,

Published:

16 February 2021

Citation:

US Cardiology Review 2021;15:e01.

DOI:

https://doi.org/10.15420/usc.2020.17
  • Views: Views 2603
  • Downloads: Downloads 140

HDL Cholesterol and Adverse Outcomes

Marc P Allard-Ratick

,

Pratik Sandesara

,

Arshed A Quyyumi

,

Laurence S Sperling

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):49–53

DOI:

https://doi.org/10.15420/usc.2019.3.2
  • Views: Views 1961
  • Downloads: Downloads 23

Role of Drug-coated Balloons in Small-vessel Coronary Artery Disease

Michael Megaly

,

Marwan Saad

,

Emmanouil S Brilakis

,

Published:

12 March 2019

Citation:

US Cardiology Review 2019;13(1):16–20

DOI:

https://doi.org/10.15420/usc.2019.4.1
  • Views: Views 1030
  • Downloads: Downloads 24